AZN.UK

11,076

+0.33%↑

AZN.UK

11,076

+0.33%↑

AZN.UK

11,076

+0.33%↑

AZN.UK

11,076

+0.33%↑

AZN.UK

11,076

+0.33%↑

Search

GlaxoSmithKline PLC

Aperta

SettoreSettore sanitario

1,404 -0.28

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1393.5

Massimo

1405

Metriche Chiave

By Trading Economics

Entrata

-329M

1.4B

Vendite

470M

8B

P/E

Media del settore

16.849

34.393

EPS

0.465

Rendimento da dividendi

4.51

Margine di Profitto

18.069

Dipendenti

68,629

EBITDA

2B

3.1B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+12.08% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

4.51%

2.54%

Utili prossimi

29 ott 2025

Prossima data del Dividendo

9 ott 2025

Prossima data del' Ex Dividendo

14 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-615M

56B

Apertura precedente

1404.28

Chiusura precedente

1404

Notizie sul Sentiment di mercato

By Acuity

33%

67%

92 / 374 Classifica in Healthcare

GlaxoSmithKline PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 lug 2025, 06:50 UTC

Utili

GSK Upbeat on Guidance After Specialty Medicines Boost Sales

18 lug 2025, 09:39 UTC

I principali Market Mover

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

2 giu 2025, 10:49 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

14 mag 2025, 11:01 UTC

Acquisizioni, Fusioni, Takeovers

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - Update

14 mag 2025, 06:39 UTC

Acquisizioni, Fusioni, Takeovers

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion

12 mag 2025, 09:36 UTC

I principali Market Mover

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 lug 2025, 09:08 UTC

Discorsi di Mercato
Utili

GSK Results Look Solid, But Benefit From Temporary Effects -- Market Talk

30 lug 2025, 06:06 UTC

Utili

Correct: GSK PLC 2Q EPS 35.5p

30 lug 2025, 06:00 UTC

Utili

GSK PLC 2Q EPS 35.5p

30 lug 2025, 06:00 UTC

Utili

GSK PLC 2Q Pretax Pft GBP1.89B

30 lug 2025, 06:00 UTC

Utili

GSK PLC 2Q Net Pft GBP1.44B

30 lug 2025, 06:00 UTC

Utili

GSK PLC 2Q Adj EPS 46.5p

30 lug 2025, 06:00 UTC

Utili

GSK PLC 2Q Turnover GBP7.99B

30 lug 2025, 06:00 UTC

Utili

GSK PLC 2Q Pre-items, Pretax Pft GBP2.5B

30 lug 2025, 06:00 UTC

Utili

GSK PLC 2Q Oper Pft GBP2.02B

28 lug 2025, 10:51 UTC

Discorsi di Mercato

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

18 lug 2025, 09:05 UTC

Azioni calde

Stocks to Watch Friday: Netflix, Norfolk Southern, Amex -- WSJ

7 lug 2025, 15:00 UTC

Acquisizioni, Fusioni, Takeovers

GSK Completes Acquisition of Efimosfermin

2 giu 2025, 10:00 UTC

Acquisizioni, Fusioni, Takeovers

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225M

15 mag 2025, 15:20 UTC

Notizie principali

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

14 mag 2025, 06:08 UTC

Acquisizioni, Fusioni, Takeovers

GSK PLC to Buy Efimosfermin from Boston Pharmaceuticals

14 mag 2025, 06:03 UTC

Acquisizioni, Fusioni, Takeovers

GSK PLC: Deal Includes Potential Success-Based Milestone Payments of $800M

14 mag 2025, 06:03 UTC

Acquisizioni, Fusioni, Takeovers

GSK PLC to Pay $1.2B Upfront

14 mag 2025, 06:03 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Buy Efimosfermin for up to $2B

14 mag 2025, 06:00 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Buy Efimosfermin

12 mag 2025, 12:07 UTC

Discorsi di Mercato

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mag 2025, 07:20 UTC

Discorsi di Mercato

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

30 apr 2025, 08:54 UTC

Discorsi di Mercato
Utili

GSK Investors Turn to U.S. Policy Outlook After Solid Results -- Market Talk

30 apr 2025, 07:49 UTC

Discorsi di Mercato
Utili

GSK's Specialty Meds Sustain Growth, Blenrep Comeback Remains Key -- Market Talk

30 apr 2025, 07:06 UTC

Discorsi di Mercato
Utili

GSK Outperforms Expectations Despite RSV Vaccine Setback -- Market Talk

Confronto tra pari

Modifica del prezzo

GlaxoSmithKline PLC Previsione

Obiettivo di Prezzo

By TipRanks

12.08% in crescita

Previsioni per 12 mesi

Media 1,573.62 GBX  12.08%

Alto 2,170 GBX

Basso 1,290 GBX

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per GlaxoSmithKline PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

14 ratings

3

Acquista

8

Mantieni

3

Vendi

Sentiment

By Acuity

92 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.